Kymera Therapeutics is a seed-stage therapeutics company focused on targeting the traditionally undruggable proteome within key pathways involved in inflammation, immunity, and oncology. Our approach combines the power of effective genetic silencing with the flexibility and drug-like properties of small molecules to harness the body’s innate protein regulation machinery.
- Bruce Booth, DPhil Founder & Chief Executive Officer
- Nello Mainolfi, PhD Founder, VP of Drug Discovery
- Stuart Chaffee, PhD Founder, VP of Business Operations